O	0	1	2	2	LS	B-LST
O	1	2	.	.	.	O

O	3	11	CLINICAL	CLINICAL	JJ	B-NP
O	12	22	PROTEOMICS	PROTEOMICS	NN	I-NP
O	23	25	AT	AT	IN	B-PP
O	26	29	THE	THE	DT	B-NP
O	30	37	BEDSIDE	BEDSIDE	NN	I-NP

O	38	48	Clinically	Clinically	RB	B-ADVP
O	48	49	-	-	HYPH	B-NP
O	49	54	based	base	VBN	I-NP
O	55	65	proteomics	proteomic	NNS	I-NP
O	66	69	has	have	VBZ	B-VP
O	70	71	a	a	DT	B-NP
O	72	77	large	large	JJ	I-NP
O	78	87	potential	potential	NN	I-NP
O	88	91	for	for	IN	B-PP
O	92	95	the	the	DT	B-NP
O	96	107	development	development	NN	I-NP
O	108	110	of	of	IN	B-PP
O	111	121	strategies	strategy	NNS	B-NP
O	122	127	which	which	WDT	B-NP
O	128	131	aim	aim	VBP	B-VP
O	132	134	to	to	TO	I-VP
O	135	144	alleviate	alleviate	VB	I-VP
O	145	149	risk	risk	NN	B-NP
O	150	160	associated	associate	VBN	B-VP
O	161	165	with	with	IN	B-PP
B-Organ	166	173	cardiac	cardiac	JJ	B-NP
O	174	181	disease	disease	NN	I-NP
O	181	182	.	.	.	O

O	183	193	Biomarkers	Biomarker	NNS	B-NP
O	194	198	that	that	WDT	B-NP
O	199	202	are	be	VBP	B-VP
O	203	207	used	use	VBN	I-VP
O	208	210	in	in	IN	B-PP
O	211	219	clinical	clinical	JJ	B-NP
O	220	228	practice	practice	NN	I-NP
O	229	232	are	be	VBP	B-VP
O	233	239	highly	highly	RB	B-ADJP
O	240	246	useful	useful	JJ	I-ADJP
O	247	249	in	in	IN	B-SBAR
O	250	254	that	that	IN	I-SBAR
O	255	259	they	they	PRP	B-NP
O	260	267	support	support	VBP	B-VP
O	268	275	medical	medical	JJ	B-NP
O	276	284	decision	decision	NN	I-NP
O	285	291	making	making	NN	I-NP
O	291	292	,	,	,	O
O	293	295	by	by	IN	B-PP
O	296	309	complementing	complement	VBG	B-VP
O	310	315	other	other	JJ	B-NP
O	316	326	diagnostic	diagnostic	JJ	I-NP
O	327	332	tests	test	NNS	I-NP
O	332	333	,	,	,	O
O	334	338	such	such	JJ	B-PP
O	339	341	as	as	IN	I-PP
O	342	345	the	the	DT	B-NP
O	346	353	medical	medical	JJ	I-NP
O	354	361	history	history	NN	I-NP
O	361	362	,	,	,	O
O	363	371	physical	physical	JJ	B-NP
O	372	383	examination	examination	NN	I-NP
O	383	384	,	,	,	O
O	385	388	and	and	CC	O
O	389	396	various	various	JJ	B-NP
O	397	402	other	other	JJ	I-NP
O	403	410	special	special	JJ	I-NP
O	411	416	tests	test	NNS	I-NP
O	416	417	.	.	.	O

O	418	431	Theoretically	Theoretically	RB	B-ADVP
O	431	432	,	,	,	O
O	433	438	there	there	EX	B-NP
O	439	442	are	be	VBP	B-VP
O	443	448	three	three	CD	B-NP
O	449	457	criteria	criterion	NNS	I-NP
O	458	462	that	that	IN	B-NP
O	462	463	,	,	,	O
O	464	466	if	if	IN	B-SBAR
O	467	476	satisfied	satisfy	VBN	B-VP
O	476	477	,	,	,	O
O	478	483	would	would	MD	B-VP
O	484	491	provide	provide	VB	I-VP
O	492	494	an	an	DT	B-NP
O	495	502	optimal	optimal	JJ	I-NP
O	503	512	biomarker	biomarker	NN	I-NP
O	513	515	of	of	IN	B-PP
O	516	519	the	the	DT	B-NP
O	520	527	disease	disease	NN	I-NP
O	528	533	state	state	NN	I-NP
O	533	534	.	.	.	O

O	535	540	First	First	RB	B-ADVP
O	540	541	,	,	,	O
O	542	545	the	the	DT	B-NP
O	546	555	potential	potential	JJ	I-NP
O	556	566	biomarkers	biomarker	NNS	I-NP
O	567	571	must	must	MD	B-VP
O	572	574	be	be	VB	I-VP
O	575	581	easily	easily	RB	B-ADJP
O	582	592	measurable	measurable	JJ	I-ADJP
O	593	595	in	in	IN	B-PP
O	596	597	a	a	DT	B-NP
O	598	603	short	short	JJ	I-NP
O	604	608	time	time	NN	I-NP
O	609	615	period	period	NN	I-NP
O	616	618	at	at	IN	B-PP
O	619	620	a	a	DT	B-NP
O	621	625	cost	cost	NN	I-NP
O	626	630	that	that	WDT	B-NP
O	631	633	is	be	VBZ	B-VP
O	634	643	practical	practical	JJ	B-ADJP
O	643	644	.	.	.	O

O	645	651	Second	Second	RB	B-ADVP
O	651	652	,	,	,	O
O	653	662	elevation	elevation	NN	B-NP
O	663	665	of	of	IN	B-PP
O	666	670	this	this	DT	B-NP
O	671	678	protein	protein	NN	I-NP
O	679	684	would	would	MD	B-VP
O	685	690	offer	offer	VB	I-VP
O	691	701	diagnostic	diagnostic	JJ	B-NP
O	702	713	information	information	NN	I-NP
O	714	718	that	that	WDT	B-NP
O	719	722	was	be	VBD	B-VP
O	723	726	not	not	RB	O
O	727	737	previously	previously	RB	B-ADJP
O	738	745	present	present	JJ	I-ADJP
O	746	748	in	in	IN	B-PP
O	749	752	the	the	DT	B-NP
O	753	760	absence	absence	NN	I-NP
O	761	763	of	of	IN	B-PP
O	764	767	the	the	DT	B-NP
O	768	775	protein	protein	NN	I-NP
O	775	776	.	.	.	O

O	777	782	Third	Third	RB	B-ADVP
O	782	783	,	,	,	O
O	784	787	the	the	DT	B-NP
O	788	799	information	information	NN	I-NP
O	800	808	obtained	obtain	VBN	B-VP
O	809	814	would	would	MD	B-VP
O	815	818	aid	aid	VB	I-VP
O	819	821	in	in	IN	B-PP
O	822	825	the	the	DT	B-NP
O	826	833	medical	medical	JJ	I-NP
O	834	842	decision	decision	NN	I-NP
O	843	849	making	make	VBG	B-VP
O	850	857	process	process	NN	B-NP
O	858	867	performed	perform	VBN	B-VP
O	868	870	by	by	IN	B-PP
O	871	874	the	the	DT	B-NP
O	875	884	clinician	clinician	NN	I-NP
O	885	886	[	[	(	O
O	886	888	11	11	CD	B-NP
O	888	889	]	]	)	O
O	889	890	.	.	.	O

O	891	902	Fulfillment	Fulfillment	NN	B-NP
O	903	905	of	of	IN	B-PP
O	906	910	such	such	JJ	B-NP
O	911	919	criteria	criterion	NNS	I-NP
O	920	930	encourages	encourage	VBZ	B-VP
O	931	937	follow	follow	VB	I-VP
O	937	938	-	-	HYPH	O
O	938	940	up	up	RP	B-PRT
O	941	943	of	of	IN	B-PP
O	944	948	such	such	JJ	B-NP
O	949	950	a	a	DT	I-NP
O	951	960	biomarker	biomarker	NN	I-NP
O	961	963	in	in	IN	B-PP
O	964	969	other	other	JJ	B-NP
O	970	975	model	model	NN	I-NP
O	976	983	systems	system	NNS	I-NP
O	984	986	or	or	CC	O
O	987	994	patient	patient	NN	B-NP
O	995	1001	cohort	cohort	JJ	I-NP
O	1002	1009	samples	sample	NNS	I-NP
O	1009	1010	.	.	.	O

O	1011	1014	For	For	IN	B-PP
O	1015	1023	instance	instance	NN	B-NP
O	1023	1024	,	,	,	O
O	1025	1032	cardiac	cardiac	JJ	B-NP
O	1033	1041	troponin	troponin	NN	I-NP
O	1042	1043	I	I	CD	I-NP
O	1044	1047	has	have	VBZ	B-VP
O	1048	1052	been	be	VBN	I-VP
O	1053	1063	previously	previously	RB	I-VP
O	1064	1069	shown	show	VBN	I-VP
O	1070	1072	to	to	TO	I-VP
O	1073	1080	fulfill	fulfill	VB	I-VP
O	1081	1085	such	such	JJ	B-NP
O	1086	1094	criteria	criterion	NNS	I-NP
O	1094	1095	,	,	,	O
O	1096	1099	and	and	CC	O
O	1100	1107	further	further	RBR	B-VP
O	1108	1114	follow	follow	VB	I-VP
O	1114	1115	-	-	HYPH	O
O	1115	1117	up	up	RP	B-PRT
O	1118	1120	in	in	IN	B-PP
O	1121	1128	patient	patient	NN	B-NP
O	1129	1136	cohorts	cohort	NNS	I-NP
O	1137	1139	is	be	VBZ	B-VP
O	1140	1148	underway	underway	JJ	B-ADJP
O	1148	1149	.	.	.	O

O	1150	1158	Recently	Recently	RB	B-ADVP
O	1158	1159	,	,	,	O
O	1160	1164	this	this	DT	B-NP
O	1165	1173	approach	approach	NN	I-NP
O	1174	1177	was	be	VBD	B-VP
O	1178	1186	utilized	utilize	VBN	I-VP
O	1187	1189	to	to	TO	I-VP
O	1190	1199	ascertain	ascertain	VB	I-VP
O	1200	1207	whether	whether	IN	B-SBAR
O	1208	1215	Cardiac	Cardiac	JJ	B-NP
O	1216	1224	Troponin	Troponin	NN	I-NP
O	1225	1226	I	I	CD	I-NP
O	1227	1228	(	(	(	O
O	1228	1231	CTN	CTN	NN	B-NP
O	1232	1233	I	I	CD	I-NP
O	1233	1234	)	)	)	O
O	1235	1237	or	or	CC	O
O	1238	1246	Creatine	Creatine	NN	B-NP
O	1247	1253	Kinase	Kinase	NN	I-NP
O	1253	1254	-	-	HYPH	B-NP
O	1254	1263	Myoglobin	Myoglobin	NN	I-NP
O	1264	1265	(	(	(	O
O	1265	1267	CK	CK	NN	B-NP
O	1267	1268	-	-	HYPH	O
O	1268	1270	MB	MB	NN	B-NP
O	1270	1271	)	)	)	O
O	1272	1277	could	could	MD	B-VP
O	1278	1280	be	be	VB	I-VP
O	1281	1285	used	use	VBN	I-VP
O	1286	1288	as	as	IN	B-PP
O	1289	1294	short	short	JJ	B-NP
O	1294	1295	-	-	HYPH	I-NP
O	1295	1299	term	term	NN	I-NP
O	1300	1302	or	or	CC	I-NP
O	1303	1307	long	long	JJ	I-NP
O	1307	1308	-	-	HYPH	I-NP
O	1308	1312	term	term	NN	I-NP
O	1313	1320	markers	marker	NNS	I-NP
O	1321	1323	of	of	IN	B-PP
O	1324	1328	risk	risk	NN	B-NP
O	1329	1339	associated	associate	VBN	B-VP
O	1340	1344	with	with	IN	B-PP
B-Organ	1345	1352	cardiac	cardiac	JJ	B-NP
O	1353	1360	surgery	surgery	NN	I-NP
O	1361	1362	[	[	(	O
O	1362	1364	12	12	CD	B-NP
O	1364	1365	]	]	)	O
O	1365	1366	.	.	.	O

O	1367	1369	In	In	IN	B-PP
O	1370	1374	this	this	DT	B-NP
O	1375	1380	study	study	NN	I-NP
O	1380	1381	,	,	,	O
O	1382	1383	a	a	DT	B-NP
O	1384	1391	patient	patient	NN	I-NP
O	1392	1398	cohort	cohort	NN	I-NP
O	1399	1401	of	of	IN	B-PP
O	1402	1405	252	252	CD	B-NP
O	1406	1417	individuals	individual	NNS	I-NP
O	1418	1421	who	who	WP	B-NP
O	1422	1425	had	have	VBD	B-VP
O	1426	1435	undergone	undergo	VBN	I-VP
B-Organ	1436	1443	cardiac	cardiac	JJ	B-NP
O	1444	1451	surgery	surgery	NN	I-NP
O	1452	1455	was	be	VBD	B-VP
O	1456	1460	used	use	VBN	I-VP
O	1461	1463	to	to	TO	B-VP
O	1464	1471	analyze	analyze	VB	I-VP
O	1472	1478	levels	level	NNS	B-NP
O	1479	1481	of	of	IN	B-PP
O	1482	1487	these	these	DT	B-NP
O	1488	1491	two	two	CD	I-NP
O	1492	1500	proteins	protein	NNS	I-NP
O	1501	1503	in	in	IN	B-PP
B-Organism_substance	1504	1509	blood	blood	NN	B-NP
O	1509	1510	.	.	.	O

O	1511	1514	Not	Not	RB	B-CONJP
O	1515	1519	only	only	RB	I-CONJP
O	1520	1523	was	be	VBD	O
O	1524	1527	CTN	CTN	NN	B-NP
O	1527	1528	-	-	HYPH	B-NP
O	1528	1529	I	I	NN	I-NP
O	1530	1535	shown	show	VBN	B-VP
O	1536	1538	to	to	TO	I-VP
O	1539	1541	be	be	VB	I-VP
O	1542	1543	a	a	DT	B-NP
O	1544	1550	strong	strong	JJ	I-NP
O	1551	1560	predictor	predictor	NN	I-NP
O	1561	1563	of	of	IN	B-PP
O	1564	1573	mortality	mortality	NN	B-NP
O	1573	1574	,	,	,	O
O	1575	1578	but	but	CC	O
O	1579	1588	increases	increase	NNS	B-NP
O	1589	1591	in	in	IN	B-PP
O	1592	1595	the	the	DT	B-NP
O	1596	1602	levels	level	NNS	I-NP
O	1603	1605	of	of	IN	B-PP
O	1606	1610	this	this	DT	B-NP
O	1611	1618	protein	protein	NN	I-NP
O	1619	1623	also	also	RB	B-ADVP
O	1624	1634	correlated	correlate	VBD	B-VP
O	1635	1639	well	well	RB	B-ADVP
O	1640	1644	with	with	IN	B-PP
O	1645	1654	increases	increase	NNS	B-NP
O	1655	1657	in	in	IN	B-PP
O	1658	1667	mortality	mortality	NN	B-NP
O	1667	1668	.	.	.	O

O	1669	1677	Findings	Finding	NNS	B-NP
O	1678	1682	from	from	IN	B-PP
O	1683	1687	this	this	DT	B-NP
O	1688	1693	study	study	NN	I-NP
O	1694	1701	support	support	VBP	B-VP
O	1702	1705	the	the	DT	B-NP
O	1706	1717	utilization	utilization	NN	I-NP
O	1718	1720	of	of	IN	B-PP
O	1721	1728	patient	patient	NN	B-NP
O	1729	1736	cohorts	cohort	NNS	I-NP
O	1737	1739	as	as	IN	B-PP
O	1740	1741	a	a	DT	B-NP
O	1742	1747	means	means	NN	I-NP
O	1748	1750	to	to	TO	B-VP
O	1751	1755	ease	ease	VB	I-VP
O	1756	1759	the	the	DT	B-NP
O	1760	1770	transition	transition	NN	I-NP
O	1771	1775	from	from	IN	B-PP
O	1776	1781	bench	bench	NN	B-NP
O	1782	1784	to	to	TO	B-PP
O	1785	1792	bedside	bedside	NN	B-NP
O	1792	1793	.	.	.	O

